Emtricitabine-13C,15N2

• UNSPSC Description:

  Emtricitabine-13C,15N2 (BW1592-13C,15N2) is a 13C- and 15N-labeled Emtricitabine (HY-17427). Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) with an EC50 of 0.01 μM in PBMC cell. It is an antiviral agent for the treatment of HIV infection.

• Target Antigen:

  Endogenous Metabolite; HIV; Isotope-Labeled Compounds; Reverse Transcriptase

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease;Others

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/emtricitabine-13c-15n2.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=[13C]1[15N](C=C(C(N)=[15N]1)F)[C@H]2O[C@H](SC2)CO

• Molecular Weight:

  250.23

• References & Citations:

  [1]Xu P, et al. Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro. J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.|[2]Faltz M, et al. Effect of the Anti-retroviral Drugs Efavirenz, Tenofovir and Emtricitabine on Endothelial Cell Function: Role of PARP. Cardiovasc Toxicol. 2017 Jan 3. [Epub ahead of print]|[3]Szczech GM, Wang LH, Walsh JP, Reproductive toxicology profile of emtricitabine in mice and rabbits. Reprod Toxicol. 2003 Jan-Feb;17(1):95-108.|[4]Saag MS, et al. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus. Clin Infect Dis. 2006 Jan 1;42(1):126-31.|[5]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.

• Shipping Conditions:

  Room temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  1217820-69-3